397 related articles for article (PubMed ID: 1970751)
1. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
Lin TH; Chu TM
Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
[TBL] [Abstract][Full Text] [Related]
2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
3. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
Ohnishi H; Lin KM; Chu TM
Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
Chao TY; Ohnishi H; Chu TM
Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
[TBL] [Abstract][Full Text] [Related]
5. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
7. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
8. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
9. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2-mediated suppression of murine lymphokine-activated killer cell activity generated from tumor-bearing hosts by interferon-gamma.
Nakajima I; Chu TM
Mol Biother; 1990 Dec; 2(4):228-32. PubMed ID: 2126942
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
12. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
13. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
Ballas ZK; Rasmussen W
J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
